retatrutide phase 2 trial results weight loss just delivered the first top-line 3 for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Triple–Hormone-Receptor Agonist Retatrutide for Obesity

It may be tempting to reuse needles, but doing so can lead to skin infections and bruising

Hypotension consider reducing antihypertensive medicines before initiating treatment or before a dose increase Diabetic ketoacidosis (DKA) increased risk (see below) SGLT-2 inhibitor use is associated with an increased risk of severe DKA People taking SGLT-2 inhibitors are at increased risk of DKA, particularly in the first few months of treatment or peri-operatively

Targeting metabolism, insulin resistance, and diabetes to treat nonalcoholic steatohepatitis

one common approach began at 0.5 mg once weekly , with incremental increases at approximately four-weekly intervals up to target maintenance doses of 4 mg, 8 mg, or 12 mg once weekly

All brands and products mentioned work identically for both medications